Opioid-induced hyperalgesia (OIH) is defined as a state of nociceptive sensitization caused by exposure to opioids. The condition is characterized by a paradoxical response whereby a patient receiving opioids for the treatment of pain could actually become more sensitive to certain painful stimuli. The type of pain experienced might be the same as the underlying pain or might be different from the original underlying pain. OIH appears to be a distinct, definable, and characteristic phenomenon that could explain loss of opioid efficacy in some patients.
Faculty: Jeffrey A. Gudin, MD
This 1-hour CME activity is designed for all clinicians who treat chronic pain.
Upon completion of this activity, participants should be better able to:
- Define opioid-induced hyperalgesia (OIH).
- Differentiate progression of underlying pain from OIH.
- Discuss mechanisms for the sensitization of spinal neurons.
- Describe therapeutic options for OIH.
Jeffrey A. Gudin, MD, has been the director of pain management and palliative care at Englewood Hospital and Medical Center, a Mount Sinai University School of Medicine teaching affiliate in New Jersey, for the past 16 years. He remains active in teaching and research, and has lectured internationally on a variety of topics in pain management, palliative care, and addiction medicine. Dr. Gudin is board certified in pain management, anesthesiology, addiction medicine, and hospice and palliative medicine. Dr. Gudin is recognized nationally as a leader in pain management. He is an experienced researcher, consultant, speaker, and speaker trainer. He has collaborated with numerous initiatives to enhance responsible prescribing and the safe use of opioid pain medications.
Staff and Content Validation Reviewer Disclosures
The staff involved with this activity and any content validation reviewers of this activity have reported no relevant financial relationships with commercial interests.
Planning Committee/Faculty Disclosure
Dr. Gudin reports that he receives speaker bureau fees from Purdue Pharma, Salix, Teva, Astra Zeneca, Iroko, Xenoport, Depomed and Kaleo. He also receives consultant fees from INSYS Therapeutics.
Debra Nelson-Hogan, Director of Education for the Academy of Integrative Pain Management, reports that she has nothing to disclose.
Cathleen Coneghen, Assistant Director of Education for the Academy of Integrative Pain Management, reports that she has nothing to disclose.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.
For questions regarding CME for this activity, you may reach the department of education at the Academy of Integrative Pain Management at email@example.com.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 APA
- 1.00 Document of Attendance
- 1.00 Nursing Credit